Zacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per Share

Brokerages expect that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will report ($0.66) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals reported earnings per share of ($0.55) during the same quarter last year, which indicates a negative year over year growth rate of 20%. The business is scheduled to report its next earnings report on Friday, March 9th.

On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($2.82) per share for the current year, with EPS estimates ranging from ($2.84) to ($2.80). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.23) per share, with EPS estimates ranging from ($3.28) to ($3.18). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Corvus Pharmaceuticals.

Several research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.25.

Corvus Pharmaceuticals (NASDAQ:CRVS) traded up $0.25 during trading hours on Tuesday, hitting $8.16. 79,125 shares of the stock traded hands, compared to its average volume of 87,317. Corvus Pharmaceuticals has a one year low of $7.54 and a one year high of $22.14. The company has a market cap of $168.12 and a P/E ratio of -3.03.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller bought 10,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $10.79 per share, for a total transaction of $107,900.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 46.40% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its position in shares of Corvus Pharmaceuticals by 121.2% during the 2nd quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after acquiring an additional 8,200 shares in the last quarter. New York State Common Retirement Fund boosted its position in Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after buying an additional 9,099 shares in the last quarter. State Street Corp boosted its position in Corvus Pharmaceuticals by 18.6% in the second quarter. State Street Corp now owns 62,475 shares of the company’s stock valued at $756,000 after buying an additional 9,779 shares in the last quarter. Teachers Advisors LLC boosted its position in Corvus Pharmaceuticals by 338.4% in the second quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock valued at $188,000 after buying an additional 12,017 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Corvus Pharmaceuticals by 81.6% in the second quarter. Bank of New York Mellon Corp now owns 28,978 shares of the company’s stock valued at $351,000 after buying an additional 13,023 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per Share” was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/zacks-brokerages-anticipate-corvus-pharmaceuticals-inc-crvs-to-announce-0-66-earnings-per-share.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply